• Trevor Perrior, CEO, Domainex
    Our medicinal chemists believe that 'every compound counts' - Dr Trevor Perrior, CEO
    Every Compound Counts
  • Domainex is committed to the support of exciting and cutting-edge translational research
    Domainex is committed to the support of exciting and cutting-edge translational research
    Translational Research
  • Domainex applies unique technologies to overcome common drug discovery challenges
    Domainex applies unique technologies to overcome common drug discovery challenges
    Overcome Challenges
  • Domainex is developing an exciting pipeline of drugs that effect epigenetic targets
    Domainex is developing an exciting pipeline of drugs that effect epigenetic targets
    Exciting Pipeline

Drug Discovery Services

Domainex is the fastest growing CRO in Europe.  By applying our novel proprietary technologies such as CDH and taking a focussed, integrated approach to medicinal chemistry, biochemistry and computational chemistry we can reduce your project timeline by up to 30%.

Read more

New technologies

Domainex has received an award of £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs). Here's a short video explaining how the technology works. GPCRs video.

Read more

Technology

FragmentBuilder logo
FragmentBuilder:
Fragment screening using MicroScale Thermophoresis


Combinatorial Domain Hunting logo
Combinatorial Domain Hunting
: Protein expression and purification services.


BioassayBuilder logo
BioassayBuilder
: Bioassay services, assay development, HTS and compound testing services.


LeadBuilder logo
LeadBuilder
: Virtual hit screening platform.

Events

8th April to 12th April 2019
San Diego, USA
17th June to 21st June 2019
Boston, USA